555 related articles for article (PubMed ID: 34975896)
1. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.
Wang K; Wang C; Jiang H; Zhang Y; Lin W; Mo J; Jin C
Front Immunol; 2021; 12():792781. PubMed ID: 34975896
[TBL] [Abstract][Full Text] [Related]
2. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
Jiang Y; Han QJ; Zhang J
World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
5. Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations.
da Costa AC; Sodergren M; Jayant K; Santa Cruz F; Spalding D; Pai M; Habib N
World J Gastroenterol; 2020 May; 26(17):2040-2048. PubMed ID: 32536773
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
7. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
8. A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma.
Xiao T; Hu S; Dong S; Cai Q; Gong W; Zhang Y; Long C; Li X
Int Immunopharmacol; 2024 Jun; 134():112144. PubMed ID: 38733820
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for hepatocellular carcinoma: Current and future.
Johnston MP; Khakoo SI
World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
[TBL] [Abstract][Full Text] [Related]
10. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Caraballo Galva LD; Cai L; Shao Y; He Y
J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma.
Dumolard L; Ghelfi J; Roth G; Decaens T; Macek Jilkova Z
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575734
[TBL] [Abstract][Full Text] [Related]
12. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
[TBL] [Abstract][Full Text] [Related]
13. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
[TBL] [Abstract][Full Text] [Related]
14. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
[TBL] [Abstract][Full Text] [Related]
15. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
Hou J; Zhang H; Sun B; Karin M
J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY; Zhu Y; Xie SZ; Qin LX
J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
[TBL] [Abstract][Full Text] [Related]
17. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
Yegin EG; Oymaci E; Karatay E; Coker A
Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
[TBL] [Abstract][Full Text] [Related]
18. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Lee YH; Tai D; Yip C; Choo SP; Chew V
Front Immunol; 2020; 11():568759. PubMed ID: 33117354
[TBL] [Abstract][Full Text] [Related]
19. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
20. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update.
Arellano RS
Curr Oncol Rep; 2020 Jul; 22(10):105. PubMed ID: 32725433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
